Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Broadfin Capital Opens a Stake in Celsus, Another Biotech Company Today

Broadfin Capital, Celsus: Broadfin Capital, managed by Kevin Kotler, just disclosed a position in Celsus Therapeutics (OTCQB: CLSXY). According to a SEC filing, Broadfin purchased around 3.5 million shares of Celsus, which represents an 8.9% position in the company. At the current price of Celsus’s stock, the value of Broadfin’s position in the company amounts to over $14 million. Earlier today, Broadfin Capital also disclosed initiating a stake in another biopharmaceutical company, Idera Pharmaceuticals.


Celsus Therapeutics recently entered into a securities purchasing agreement, which will bring the company gross proceeds worth some $12.5 million. Under the agreement, Celsus sold around 22 million ordinary shares at a price of $0.57 apiece to a group of unnamed institutional healthcare investors. Celsus Therapeutics is a clinical stage company engaged in the development of a new type of anti-inflamatory drugs.

Disclosure: none

Recommended Reading:

Kevin Kotler’s Broadfin Capital Joins HealthCor in Idera

Phil Frohlich’s Prescott Group Is Buying More China Marine Food Stock

Columbia Wanger Asset Management Loves Boingo Wireless, Closes Out on This Trio

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!